PDGFRB function in lymphoma progression
Description: The large cell anaplastic lymphoma (ALCL) is a highly aggressive T-cell non-Hodgkin`s lymphoma, and often associated with a t(2,5) translocation, which leads to activation of the NPM-ALK fusion protein. Our recent studies identified NPM-ALK as an activator of the AP-1 transcription factors (TF) JUNB and cJun. This TF complex activates the molecule PDGFRB on lymphoma cells and promotes tumor progression and metastasis in a NPM-ALK lymphoma mouse model. The genetic loss of cJun and JUNB in this model system has no effect on tumor incidence, however, reduces the spread of the tumor by reduction of the blood vessels in the tumor, resulting in a reduced tumor growth rate and prolonged survival time of the animals. The treatment of tumors with an inhibitor of PDGFRB (imatinib) also results in a significantly reduced tumor growth and prolonged survival rate of NPM-ALK mice. In addition, treatment with imatinib in a therapy-resistant NPM-ALK-positive ALCL patient resulted in a rapid, complete and long-lasting cure to date. Analysis of a large cohort of NPM-ALK ALCL patients shows that PDGFRB expression on ALCL tumors is significantly associated with poor prognosis compared to patients with PDGFRB negative tumors. We conclude that the cJun / JUNB controlled activity of PDGFRB has an important function in the activation of tumor growth and together with increased PDGFRB activity in stromal cells and in the micro-environment of the tumor promotes rapid tumor expansion in the body. This suggests a dual function of PDGFRB pathway: firstly,: it promotes growth of tumor cells, and secondly, it stimulates the PDGFRB expression in stromal cells in ALCL ALK+ tumors. The focus of this project proposal is to investigate the dual function both in the PDGFRB tumor in stromal cells of ALCL. We also want to investigate the tumor-stroma interaction controlled by PDGFRB and its ligand PDGF tumor-stroma interaction in NPM-ALK lymphomas. To make this possible, we will genetically delete the PDGFRB in tumor cells or stromal fibroblasts or both, to study its function in both compartments of these lymphomas. The tumor-specific deletion of PDGFRB is facilitated in mouse models with PDGFRB-specific expression in tumor cells (with CD4-Cre), and stromal cells can be turned off (via FSP-Cre). The impact of the loss of PDGFRB is investigated histologically, cell biologically but also on a molecular level. Our goal is to better understand the contribution of PDGFRB on tumor-stroma interaction in the formation and spread of ALCL. An improved understanding of these effects should lead directly to new diagnostic and therapeutic strategies for NPM-ALK patients.
Funder: Austrian Science Fund
Amount: €350,600
Funding type: grant
Funder scheme: Principal Investigator Projects
Start date: 2016-08-01
End date: 2022-01-31
Investigator: Lukas Kenner (lead)
Institutions: Medical University of Vienna, Medizinische Universität Wien
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Funded outputs count: 42
Funder award ID: P29251
OpenAlex ID: G4637812876
